SESIP Paves the Way for IoT Manufacturers to Meet New European Cybersecurity Rules
12.12.2024 09:00:00 CET | Business Wire | Press release
GlobalPlatform’s SESIP methodology (EN 17927) offers a streamlined, cost-effective security framework for connected devices and components to conform to the EU’s new Cyber Resilience Act
GlobalPlatform is calling for manufacturers of connected devices and components to adopt its “Security Evaluation Standard for IoT Platforms” (SESIP) methodology to demonstrate conformance with the European Union’s new Cyber Resilience Act (CRA), which comes into force this month. The CRA aims to strengthen and harmonize cybersecurity across the EU by creating a new legal framework for all products that connect to the internet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211681976/en/

(Graphic: Business Wire)
The enactment of the CRA puts into place mandatory cybersecurity rules that span the entire lifecycle of a digital product sold in the EU. The CRA was published in the Official Journal of the European Union last month and becomes law on December 11, 2024. Product manufacturers will have 36 months to fully comply with the legislation. The Act will eventually require all relevant products to comply with the rules in order to obtain the CE marking, a mandatory market requirement for issuing products in Europe.
As an internationally recognized standard for IoT security evaluation, SESIP is key to meeting the requirements mandated by the CRA. It provides manufacturers with a proven methodology for conducting security evaluations of software and hardware components across their products and supply chains. SESIP is recognized as a standard by CENELEC, the European Standardization Organization, as EN 17927. It also aligns with many other legislation and vertical certification schemes around the world, including the Cyber Trust Mark in the US.
The methodology is being used to certify components, platforms, and modules from a range of companies and is supported by a growing ecosystem of security providers, certification bodies (CBs), security laboratories, and other stakeholders. GlobalPlatform continues to support the growth and governance of the SESIP ecosystem. SGS Brightsight has recently been accredited as a SESIP CB following approval from the Spanish national accreditation body (ENAC), becoming the second SESIP CB after TrustCB.
“Industry support for SESIP is building at this critical juncture for IoT manufacturers operating in Europe,” said Gil Bernabeu, CTO of GlobalPlatform. “The Cyber Resilience Act is vital to protecting consumers and businesses by embedding security features into the heart of the connected devices we use every day, providing a cybersecurity framework that spans the design, development, and maintenance of digital products.
“However, this landmark legislation presents a range of compliance challenges for manufacturers of connected devices and the components used in these products,” continued Bernabeu. “SESIP simplifies conformity with the new regulations by providing a unified framework for comprehensive security evaluation, reducing cost, risk, and time to market. We look forward to expanding the SESIP ecosystem to help multiple industry sectors meet the requirements of the new European regulations. It will also enable international manufacturers to reuse their security evaluation investments to demonstrate conformance to non-European regulations.”
The SESIP methodology is already mapped to other standards and regulations such as ETSI, (EN 303645 / TS 103732), ISO/IEC (62443-4-2), RED (EN 18031), UNECE WP.29 (ISO/SAE 21434) and NIST (NIST 8259 / NIST 8425). It is also being used by schemes such as PSA Certified, and standardization bodies including the Car Connectivity Consortium and the Wireless Power Consortium. In addition to Europe, SESIP is being adopted around the world in key markets such as China, where an agreement was recently reached between GlobalPlatform and China’s National Financial Technology Certification Center (NFTC).
GlobalPlatform has a number of initiatives in place to help accelerate SESIP adoption. A training program has been launched and available for any interested party. It has also launched the SESIP Adopters community to give non-members the ability to keep up to date with relevant technical documents and showcase certified SESIP products.
For more information on SESIP please visit: https://globalplatform.org/sesip/
About GlobalPlatform
GlobalPlatform is a technical standards organization that enables the efficient launch and management of innovative, secure-by-design digital services and devices, which deliver end-to-end security, privacy, simplicity, and convenience to users. It achieves this by providing standardized technologies and certifications that empower technology and service providers to develop, certify, deploy, and manage digital services and devices in line with their business, security, regulatory and data protection needs. GlobalPlatform technologies are used in billions of smart cards, smartphones, wearables and other connected and IoT devices.
GlobalPlatform standardized technologies and certifications are developed through effective industry-driven collaboration, led by multiple diverse member companies working in partnership with industry and regulatory bodies and other interested parties from around the world.
globalplatform.org | Twitter / X | LinkedIn | YouTube | GitHub | WeChat
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211681976/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom